Transform Deadly Cancer into a Chronic and Eventually Curable Disease
Transform Deadly Cancer into a Chronic and Eventually Curable Disease
Load image
Background image
About Us
About Us
Company Overview
As a global clinical-stage biotechnology company, our mission is the discovery and development of innovative cancer therapies across a spectrum of tumor types. Operating from R&D centers in New Jersey, U.S., and Hangzhou, China, we've brought together an experienced management team, curated a distinctive oncology pipeline, and formed partnerships with top pharmaceutical companies to accelerate drug discovery and development. We are committed to becoming an innovative biopharmaceutical company with a global footprint and strive to benefit patients worldwide.
View More
Background image Background image
Differentiated Pipeline
We have identified and developed a robust pipeline of six drug candidates.Currently, our pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates.
View More